Jardiance vs. Farxiga

See how Jardiance and Farxiga compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Jardiance and Farxiga are both once-daily SGLT2 inhibitors approved for type 2 diabetes, heart failure, and chronic kidney disease, with largely overlapping benefits.

  • Jardiance's label lists a notably higher hypoglycemia rate when combined with insulin or sulfonylureas, while Farxiga's label sets a specific eGFR cutoff for glycemic use.

  • Neither drug is approved for type 1 diabetes or diabetic ketoacidosis treatment, and both carry warnings for genital infections, volume depletion, and ketoacidosis risk.

Jardiance vs. Farxiga Drug Summary

Jardiance

Jardiance (empagliflozin) is an SGLT2 inhibitor used to manage blood sugar in type 2 diabetes and to reduce cardiovascular and kidney risks in adults with related heart or kidney disease. It comes as an oral tablet taken once daily, usually starting at 10 mg.

Farxiga

Farxiga (dapagliflozin) is also an SGLT2 inhibitor, prescribed for blood sugar control in type 2 diabetes as well as for heart failure and chronic kidney disease. It is an oral tablet taken once daily, typically starting at 5 mg.

Jardiance vs. Farxiga Side Effects

Jardiance

Most common
Hypoglycemia with insulin/SU (up to 41.3%)
Volume depletion related reactions (up to 11.4%)
Urinary tract infection (up to 9.3%)
Female genital mycotic infection (up to 5.4%)

Farxiga

Most common
Female genital mycotic infections (up to 6.9%)
Nasopharyngitis (up to 6.3%)
Urinary tract infections (up to 4.3%)
Back pain (up to 4.2%)

Jardiance vs. Farxiga Dosage

Jardiance

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 10 mg once daily At the start
Maximum dose 25 mg once daily If needed
Dose changes 1 increase As tolerated

Farxiga

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 5 mg once daily At the start
Maximum dose 10 mg once daily If needed
Dose changes 1 increase As tolerated

Jardiance vs. Farxiga Indications

Jardiance

Jardiance is approved to lower blood sugar in type 2 diabetes, reduce cardiovascular death in people with type 2 diabetes and heart disease, and treat heart failure regardless of ejection fraction. It is also approved to slow chronic kidney disease progression and lower the risk of kidney failure, cardiovascular death, and related hospitalization.

  • Blood sugar control in adults and children 10+ with type 2 diabetes

  • Reduce cardiovascular death in type 2 diabetes with heart disease

  • Reduce death and hospitalization in heart failure, any ejection fraction

  • Slow chronic kidney disease progression and reduce related hospitalization

Farxiga

Farxiga is approved to lower blood sugar in type 2 diabetes, reduce heart failure hospitalization in people with type 2 diabetes and cardiovascular risk factors, and treat heart failure across both reduced and preserved ejection fraction. It is also approved to slow chronic kidney disease progression and lower the risk of kidney failure and cardiovascular death.

  • Blood sugar control in adults and children 10+ with type 2 diabetes

  • Reduce heart failure hospitalization risk in type 2 diabetes

  • Treat heart failure across reduced and preserved ejection fraction

  • Slow chronic kidney disease progression and reduce kidney failure risk

Jardiance vs. Farxiga Pros and Cons

Jardiance

Jardiance's label highlights a specific cardiovascular death indication for people with established heart disease and does not spell out an eGFR floor or dialysis contraindication for glycemic use. It also reports a notably high hypoglycemia rate when combined with insulin or sulfonylureas, along with higher rates of volume depletion and urinary tract infection than Farxiga's label shows.

Pros

  • FDA-approved specifically to reduce cardiovascular death in type 2 diabetes with existing heart disease

  • No labeled eGFR cutoff stated for glycemic use, unlike Farxiga's 45 mL/min/1.73m2 floor

  • No labeled dialysis contraindication, unlike Farxiga

Cons

  • Hypoglycemia risk can reach up to 41.3% when combined with insulin or sulfonylureas

  • Volume depletion reactions reported in up to 11.4% of patients

  • Higher urinary tract infection rate (up to 9.3%) than Farxiga's (up to 4.3%)

Farxiga

Farxiga's label extends its heart-related indication to people with only cardiovascular risk factors, not just diagnosed disease, and reports lower hypoglycemia and volume depletion rates than Jardiance. It does specify an eGFR floor of 45 mL/min/1.73m2 for glycemic benefit and is contraindicated in dialysis, with a slightly higher genital mycotic infection rate than Jardiance's label shows.

Pros

  • Lower reported rates of hypoglycemia and volume depletion in its label

  • Lower urinary tract infection rate (up to 4.3%) than Jardiance's (up to 9.3%)

  • Covers a broader early population for heart-related risk reduction, including those with only cardiovascular risk factors

Cons

  • Not recommended for glycemic control at eGFR below 45 mL/min/1.73m2

  • Contraindicated in severe renal impairment or dialysis

  • Slightly higher genital mycotic infection rate (up to 6.9%) than Jardiance's (up to 5.4%)

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.